SRS治疗转移瘤.pdfVIP

  • 6
  • 0
  • 约4.93万字
  • 约 7页
  • 2017-07-03 发布于浙江
  • 举报
SRS治疗转移瘤

Wu et al. Radiation Oncology 2011, 6:84 /content/6/1/84 RESEARCH Open Access Clinical Analysis of stereotactic body radiation therapy using extracranial gamma knife for patients with mainly bulky inoperable early stage non-small cell lung carcinoma 1,2† 1† 2 2 1* Dajun Wu , Hong Zhu , Hanjun Tang , Changlin Li and Feng Xu Abstract Purpose: To evaluate the clinical efficacy and toxicity of stereotactic body radiation therapy (SBRT) using extracranial gamma knife in patients with mainly bulky inoperable early stage non-small cell lung carcinoma (NSCLC). Materials and methods: A total of 43 medically inoperable patients with mainly bulky Stage I/II NSCLC received SBRT using gamma knife were reviewed. The fraction dose and the total dose were determined by the radiation oncologist according to patients’ general status, tumor location, tumor size and the relationship between tumor and nearby organ at risk (OAR). The total dose of 34~47.5 Gy was prescribed in 4~12 fractions, 3.5~10 Gy per fraction, one fraction per day or every other day. The therapeutic efficacy and toxicity were evaluated. Results: The median follow-up was 22 months (range, 3-102 months). The local tumor response rate was 95.35%, with CR 18.60% (8/43) and PR 76.74% (33/43), respectively. The local control rates at 1, 2, 3, 5 years were 77.54%, 53.02%, 39.77%, and 15.46%, respectively, while the 1- and 2-year local control rates were 75% and 60% for tumor ≤3 cm; 84% and 71% for tumor sized 3~5 cm; 55% and 14.6% for tumor sized 5~7 cm; and 45%, 21% in those with tumor size of 7 cm. The overall survival rate at 1, 2, 3, 5 years were 92.04%, 78.04%, 62.76%, 42.61%, respectively. The toxicity of stereotactic radiation therapy was grade 1-2. Clinical stages w

文档评论(0)

1亿VIP精品文档

相关文档